A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases. The purpose of this study is to determine if ABBV-1480 plus chemotherapy works better than pembrolizumab plus chemotherapy in adult participants with NSCLC. ABBV-1480 is an investigational drug being developed for the treatment of NSCLC. Participants will be randomized into 2 groups. One group will receive ABBV-1480 with platinum based chemotherapy. Another group will receive standard of care (SOC) pembrolizumab wit

Trial Details

NCT ID
NCT07756645
Phase
PHASE3
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ABBV-1480
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel
  • Nab- Paclitaxel
Locations (sample)
  • Fort Wayne, Indiana, United States|41.1306,-85.12886
  • Rio Piedras, Puerto Rico|18.39745,-66.04989

Key Eligibility Criteria

  • Adult subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or IV sqNSCLC that is not amenable to curative treat…
  • At least one lesion with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the local site inv…
  • Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →